<div id="readability-page-1"><p>QuidelOrtho Corporation (NASDAQ:QDEL - Get Free Report) Director Ann Rhoads bought 750 shares of the firm's stock in a transaction dated Wednesday, December 10th. The shares were acquired at an average cost of $28.27 per share, with a total value of $21,202.50. Following the completion of the transaction, the director owned 15,021 shares of the company's stock, valued at $424,643.67. This represents a 5.26% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link.</p><h2>QuidelOrtho Stock Up 5.0%</h2><ul><li>Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11</li></ul><p>NASDAQ QDEL traded up $1.36 during trading hours on Wednesday, hitting $28.80. The company's stock had a trading volume of 1,427,468 shares, compared to its average volume of 1,334,466. The company has a market capitalization of $1.96 billion, a PE ratio of -1.69 and a beta of 0.58. The company has a current ratio of 1.78, a quick ratio of 0.98 and a debt-to-equity ratio of 1.23. QuidelOrtho Corporation has a 52 week low of $19.50 and a 52 week high of $49.45. The company's 50-day simple moving average is $26.47 and its two-hundred day simple moving average is $27.49. </p><p>QuidelOrtho (NASDAQ:QDEL - Get Free Report) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.80 EPS for the quarter, topping analysts' consensus estimates of $0.51 by $0.29. QuidelOrtho had a positive return on equity of 5.75% and a negative net margin of 42.53%.The firm had revenue of $699.90 million during the quarter, compared to analyst estimates of $667.45 million. During the same period in the previous year, the company posted $0.85 EPS. The company's revenue for the quarter was down 3.7% on a year-over-year basis. QuidelOrtho has set its FY 2025 guidance at 2.000-2.150 EPS.  Research analysts anticipate that  QuidelOrtho Corporation will post 2.3 EPS for the current fiscal year. </p><h2>Analysts Set New Price Targets</h2><p>Several analysts have recently commented on QDEL shares. Zacks Research downgraded shares of QuidelOrtho from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a report on Monday, October 13th. UBS Group upped their price objective on shares of QuidelOrtho from $26.00 to $31.00 and gave the stock a &#34;neutral&#34; rating in a research report on Thursday, November 6th. JPMorgan Chase &amp; Co. cut their target price on QuidelOrtho from $26.00 to $22.00 and set an &#34;underweight&#34; rating on the stock in a research note on Friday, November 7th. Weiss Ratings  reaffirmed a &#34;sell (e+)&#34; rating on shares of QuidelOrtho in a research report on Wednesday, October 8th. Finally, Citigroup  reissued a &#34;neutral&#34; rating and issued a $33.00 price objective (down previously from $40.00) on shares of QuidelOrtho in a research report on Tuesday, October 7th. Two investment analysts have rated the stock with a Buy rating, two have assigned  a Hold rating and three have assigned  a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of &#34;Reduce&#34; and a consensus target price of $38.20.</p><p><b>Read Our Latest Stock Report on QuidelOrtho</b></p><h2>Institutional Investors Weigh In On QuidelOrtho</h2><p>Institutional investors and hedge funds have recently modified their holdings of the company. T. Rowe Price Investment Management Inc. lifted its stake in  QuidelOrtho by 1.9% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 11,447,188 shares of the company's stock worth $400,309,000 after purchasing an additional 208,362 shares in the last quarter.  Invesco Ltd. boosted its holdings in shares of  QuidelOrtho by 10.6% in the 1st quarter. Invesco Ltd. now owns 3,813,833 shares of the company's stock worth $133,370,000 after purchasing an additional 366,387 shares in the last quarter.  Dimensional Fund Advisors LP boosted its stake in  QuidelOrtho by 14.0% in the third quarter. Dimensional Fund Advisors LP now owns 2,859,455 shares of the company's stock worth $84,208,000 after buying an additional 350,636 shares in the last quarter.  State Street Corp increased its stake in  QuidelOrtho by 23.3% in the 2nd quarter. State Street Corp now owns 2,700,940 shares of the company's stock worth $77,841,000 after purchasing an additional 510,291 shares during the period.  Finally, Newtyn Management LLC lifted its position in  QuidelOrtho by 58.3% in the third quarter. Newtyn Management LLC now owns 2,700,000 shares of the company's stock valued at $79,515,000 after purchasing an additional 994,332 shares during the last quarter. 99.00% of the stock is owned by hedge funds and other institutional investors. </p><h2>About QuidelOrtho</h2> (Get Free Report)<p>QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.</p><h2>See Also</h2><ul><li>Five stocks we like better than QuidelOrtho</li><li>High Flyers: 3 Natural Gas Stocks for March 2022</li><li>Market Momentum: 3 Stocks Poised for Major Breakouts</li><li>5 discounted opportunities for dividend growth investors</li><li>3 Reasons Casey’s General Stores Will Continue Trending Higher</li><li>What is a Special Dividend?</li><li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in QuidelOrtho Right Now?</h2><p>Before you consider QuidelOrtho, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and QuidelOrtho wasn't on the list.</p><p>While QuidelOrtho currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

QDEL

<p>QuidelOrtho Director Ann Rhoads purchased 750 shares at $28.27 each, totaling $21,202.50, increasing her stake by 5.26%. The transaction was disclosed in an SEC filing. QuidelOrtho's stock rose 5.0% to $28.80, with a market cap of $1.96 billion. Analysts have mixed ratings, with a consensus target price of $38.20. Institutional investors have adjusted their holdings, with notable increases from T. Rowe Price and others.</p>

Insider Buying: QuidelOrtho (NASDAQ:QDEL) Director Buys $21,202.50 in Stock